Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study

L. Archibugi, M. Piciucchi, S. Stigliano, R. Valente, G. Zerboni, V. Barucca, M. Milella, P. Maisonneuve, G. Delle Fave, G. Capurso

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Data on the association between aspirin and statin use and Pancreatic Ductal AdenoCarcinoma (PDAC) risk are conflicting. These drugs are often co-prescribed, but no studies evaluated the potential combined or confounding effect of the two at the same time. We aimed to investigate the association between aspirin and statin exclusive and combined use and PDAC occurrence. Data on environmental factors, family and medical history were screened in a case-control study. PDAC cases were matched to controls for age and gender. Power calculation performed ahead. Odds ratios (OR) and 95% confidence intervals(CI) were obtained from multivariable logistic regression analysis. In 408 PDAC patients and 816 matched controls, overall statin (OR 0.61; 95%CI,0.43-0.88), but not aspirin use was associated to reduced PDAC risk. Compared to non-users, exclusive statin (OR 0.51; 95%CI,0.32-0.80) and exclusive aspirin users (OR 0.64; 95%CI,0.40-1.01) had reduced PDAC risk. Concomitant statin and aspirin use did not further reduce the risk compared with statin use alone and no interaction was evident. Statin protective association was dose-dependent, and consistent in most subgroups, being stronger in smokers, elderly, obese and non-diabetic patients. The present study suggests that statin use is associated to reduced PDAC risk, supporting a chemopreventive action of statins on PDAC.
Original languageEnglish
Pages (from-to)13024
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - Oct 12 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pancreatic Neoplasms
Aspirin
Case-Control Studies
Adenocarcinoma
Odds Ratio
Confidence Intervals
Medical History Taking
Logistic Models
Regression Analysis

Cite this

Archibugi, L., Piciucchi, M., Stigliano, S., Valente, R., Zerboni, G., Barucca, V., ... Capurso, G. (2017). Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. Scientific Reports, 7(1), 13024. https://doi.org/10.1038/s41598-017-13430-z [doi]

Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. / Archibugi, L.; Piciucchi, M.; Stigliano, S.; Valente, R.; Zerboni, G.; Barucca, V.; Milella, M.; Maisonneuve, P.; Fave, G. Delle; Capurso, G.

In: Scientific Reports, Vol. 7, No. 1, 12.10.2017, p. 13024.

Research output: Contribution to journalArticle

Archibugi, L, Piciucchi, M, Stigliano, S, Valente, R, Zerboni, G, Barucca, V, Milella, M, Maisonneuve, P, Fave, GD & Capurso, G 2017, 'Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study', Scientific Reports, vol. 7, no. 1, pp. 13024. https://doi.org/10.1038/s41598-017-13430-z [doi]
Archibugi, L. ; Piciucchi, M. ; Stigliano, S. ; Valente, R. ; Zerboni, G. ; Barucca, V. ; Milella, M. ; Maisonneuve, P. ; Fave, G. Delle ; Capurso, G. / Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. In: Scientific Reports. 2017 ; Vol. 7, No. 1. pp. 13024.
@article{1900e8c7a8ff434aa8921905dabd7811,
title = "Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study",
abstract = "Data on the association between aspirin and statin use and Pancreatic Ductal AdenoCarcinoma (PDAC) risk are conflicting. These drugs are often co-prescribed, but no studies evaluated the potential combined or confounding effect of the two at the same time. We aimed to investigate the association between aspirin and statin exclusive and combined use and PDAC occurrence. Data on environmental factors, family and medical history were screened in a case-control study. PDAC cases were matched to controls for age and gender. Power calculation performed ahead. Odds ratios (OR) and 95{\%} confidence intervals(CI) were obtained from multivariable logistic regression analysis. In 408 PDAC patients and 816 matched controls, overall statin (OR 0.61; 95{\%}CI,0.43-0.88), but not aspirin use was associated to reduced PDAC risk. Compared to non-users, exclusive statin (OR 0.51; 95{\%}CI,0.32-0.80) and exclusive aspirin users (OR 0.64; 95{\%}CI,0.40-1.01) had reduced PDAC risk. Concomitant statin and aspirin use did not further reduce the risk compared with statin use alone and no interaction was evident. Statin protective association was dose-dependent, and consistent in most subgroups, being stronger in smokers, elderly, obese and non-diabetic patients. The present study suggests that statin use is associated to reduced PDAC risk, supporting a chemopreventive action of statins on PDAC.",
author = "L. Archibugi and M. Piciucchi and S. Stigliano and R. Valente and G. Zerboni and V. Barucca and M. Milella and P. Maisonneuve and Fave, {G. Delle} and G. Capurso",
note = "LR: 20171219; JID: 101563288; 2017/02/10 00:00 [received]; 2017/09/25 00:00 [accepted]; 2017/10/14 06:00 [entrez]; 2017/10/14 06:00 [pubmed]; 2017/10/14 06:00 [medline]; epublish",
year = "2017",
month = "10",
day = "12",
doi = "10.1038/s41598-017-13430-z [doi]",
language = "English",
volume = "7",
pages = "13024",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study

AU - Archibugi, L.

AU - Piciucchi, M.

AU - Stigliano, S.

AU - Valente, R.

AU - Zerboni, G.

AU - Barucca, V.

AU - Milella, M.

AU - Maisonneuve, P.

AU - Fave, G. Delle

AU - Capurso, G.

N1 - LR: 20171219; JID: 101563288; 2017/02/10 00:00 [received]; 2017/09/25 00:00 [accepted]; 2017/10/14 06:00 [entrez]; 2017/10/14 06:00 [pubmed]; 2017/10/14 06:00 [medline]; epublish

PY - 2017/10/12

Y1 - 2017/10/12

N2 - Data on the association between aspirin and statin use and Pancreatic Ductal AdenoCarcinoma (PDAC) risk are conflicting. These drugs are often co-prescribed, but no studies evaluated the potential combined or confounding effect of the two at the same time. We aimed to investigate the association between aspirin and statin exclusive and combined use and PDAC occurrence. Data on environmental factors, family and medical history were screened in a case-control study. PDAC cases were matched to controls for age and gender. Power calculation performed ahead. Odds ratios (OR) and 95% confidence intervals(CI) were obtained from multivariable logistic regression analysis. In 408 PDAC patients and 816 matched controls, overall statin (OR 0.61; 95%CI,0.43-0.88), but not aspirin use was associated to reduced PDAC risk. Compared to non-users, exclusive statin (OR 0.51; 95%CI,0.32-0.80) and exclusive aspirin users (OR 0.64; 95%CI,0.40-1.01) had reduced PDAC risk. Concomitant statin and aspirin use did not further reduce the risk compared with statin use alone and no interaction was evident. Statin protective association was dose-dependent, and consistent in most subgroups, being stronger in smokers, elderly, obese and non-diabetic patients. The present study suggests that statin use is associated to reduced PDAC risk, supporting a chemopreventive action of statins on PDAC.

AB - Data on the association between aspirin and statin use and Pancreatic Ductal AdenoCarcinoma (PDAC) risk are conflicting. These drugs are often co-prescribed, but no studies evaluated the potential combined or confounding effect of the two at the same time. We aimed to investigate the association between aspirin and statin exclusive and combined use and PDAC occurrence. Data on environmental factors, family and medical history were screened in a case-control study. PDAC cases were matched to controls for age and gender. Power calculation performed ahead. Odds ratios (OR) and 95% confidence intervals(CI) were obtained from multivariable logistic regression analysis. In 408 PDAC patients and 816 matched controls, overall statin (OR 0.61; 95%CI,0.43-0.88), but not aspirin use was associated to reduced PDAC risk. Compared to non-users, exclusive statin (OR 0.51; 95%CI,0.32-0.80) and exclusive aspirin users (OR 0.64; 95%CI,0.40-1.01) had reduced PDAC risk. Concomitant statin and aspirin use did not further reduce the risk compared with statin use alone and no interaction was evident. Statin protective association was dose-dependent, and consistent in most subgroups, being stronger in smokers, elderly, obese and non-diabetic patients. The present study suggests that statin use is associated to reduced PDAC risk, supporting a chemopreventive action of statins on PDAC.

U2 - 10.1038/s41598-017-13430-z [doi]

DO - 10.1038/s41598-017-13430-z [doi]

M3 - Article

VL - 7

SP - 13024

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

ER -